Article
Medicine, Research & Experimental
Nidhi Jalan-Sakrikar, Abid Anwar, Usman Yaqoob, Can Gan, Anthony B. Lagnado, Alexander Q. Wixom, Diana Jurk, Robert C. Huebert
Summary: This study investigated the mechanistic relationship between telomere damage and biliary fibrosis in primary sclerosing cholangitis (PSC). The results showed telomere attrition and reduced telomerase reverse transcriptase (TERT) expression in patients with PSC. Cellular models demonstrated that telomere dysfunction can lead to senescence and fibrosis, which can be rescued by modulating TERT levels.
Article
Gastroenterology & Hepatology
Julian Hercun, Mazen Noureddin, Nabil Noureddin, Jason Eccleston, Daniel Woolridge, T. Jake Liang, Michele Tana, David E. Kleiner, Gracia Viana Rodriguez, Christopher Koh, Jay H. Hoofnagle, Theo Heller
Summary: This study evaluated the involvement of bile duct and disease progression in patients with primary biliary cholangitis (PBC) and found that bile duct injury does not follow the same course as fibrosis, and certain indicators are associated with ductopenia progression.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2022)
Review
Pharmacology & Pharmacy
Garima Mishra, Pradeep Singh, Mulugeta Molla, Yohannes Shumet Yimer, Subas Chandra Dinda, Phool Chandra, Bhuvnesh Kumar Singh, Samuel Berihun Dagnew, Abraham Nigussie Assefa, Amien Ewunetie
Summary: Prolonged alcohol consumption is increasing the risk of alcohol-associated liver diseases, and the gut-liver axis plays a crucial role in their progression. Alcohol-induced gut microbiota imbalance stimulates dysbiosis, disrupts the intestinal barrier function, and triggers immune and inflammatory responses, further aggravating liver injury. Probiotics have been extensively researched to alleviate alcohol-related liver diseases and improve liver health.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Multidisciplinary Sciences
Xi Li, Yan Li, Jintao Xiao, Huiwen Wang, Yan Guo, Xiuru Mao, Pan Shi, Yanliang Hou, Xiaoxun Zhang, Nan Zhao, Minghua Zheng, Yonghong He, Jingjing Ding, Ya Tan, Min Liao, Ling Li, Ying Peng, Xuan Li, Qiong Pan, Qiaoling Xie, Qiao Li, Jianwei Li, Ying Li, Zhe Chen, Yongxiu Huang, David N. Assis, Shi-Ying Cai, James L. Boyer, Xuequan Huang, Can-E Tang, Xiaowei Liu, Shifang Peng, Jin Chai
Summary: The numbers of DUOX2(+)ACE2(+) small cholangiocytes are inversely associated with disease severity in PBC. They may be the target of pIgR-mediated humoral responses. Protecting these cells and targeting anti-pIgR autoantibodies could be valuable strategies for therapeutic interventions in PBC.
NATURE COMMUNICATIONS
(2023)
Article
Gastroenterology & Hepatology
Alexander M. Sy, Raphaella D. Ferreira, Binu V. John
Summary: Several studies have shown that patients with PBC have an increased risk of developing HCC. Risk factors for HCC in PBC include advanced age, male sex, comorbidities, and advanced liver fibrosis. The role of treatment response as a risk factor for HCC development in PBC patients should be further investigated. HCC in PBC has a poor prognosis compared to other chronic liver diseases with HCC, and liver transplantation offers the highest survival rate among available therapies.
CLINICS IN LIVER DISEASE
(2022)
Article
Gastroenterology & Hepatology
Mark R. Pedersen, Garrett Greenan, Sumant Arora, Arvind R. Murali, Marlyn J. Mayo
Summary: UDCA after LT reduces the odds of BC and bile stones and sludge in all-comer LT recipients and reduces or delays the incidence of rPBC in patients transplanted for PBC. UDCA use after LT could be considered in all LT recipients to reduce the odds of BC and may be particularly beneficial for patients transplanted for PBC by reducing the incidence of rPBC.
LIVER TRANSPLANTATION
(2021)
Article
Gastroenterology & Hepatology
Thomas W. Warnes, Stephen A. Roberts, Alexander Smith, Victor M. Cope, Patricia Vales, Raymond McMahon
Summary: This study found that measurement of baseline portal pressure is of significant prognostic value in primary biliary cholangitis, providing additional predictive information beyond Mayo score and Ludwig stage.
LIVER INTERNATIONAL
(2023)
Article
Gastroenterology & Hepatology
Debashis Haldar, Ashnila Janmohamed, Tim Plant, Matthew Davidson, Hannah Norman, Emily Russell, Olivia Serevina, Kenneth Chung, Kashif Qamar, Bridget Gunson, Bettina Hansen, Alex Richter, Palak J. Trivedi, Gideon M. Hirschfield
Summary: In patients with PBC, the presence of anti-gp210 autoantibodies is associated with adverse clinical manifestations, predicts treatment non-response, and independently predicts decreased transplant-free survival.
LIVER INTERNATIONAL
(2021)
Letter
Gastroenterology & Hepatology
Yan Li, Wen-Cheng Liu, Bing Chang
Summary: The interaction between gut microflora and liver diseases has attracted much attention. The composition of the intestinal microflora includes bacteria, archaea, fungi, and viruses. There is limited research on the intestinal virome, and its causal relationship with bacterial changes in the gut is still unclear. However, the importance of the intestinal virome in the development, diagnosis, and treatment of liver diseases cannot be denied.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Immunology
Yi-jun Zhou, Gao-xiang Ying, Shi-lei Dong, Bo Xiang, Qiao-fei Jin
Summary: The gut microbiota of PBC patients from Zhejiang Province showed lower diversity and specific alterations compared to healthy controls. Six specific genera were identified as optimal biomarkers for the diagnosis of PBC. The changes in gut microbiota were associated with lipid metabolism and biosynthesis of secondary metabolites.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Gastroenterology & Hepatology
Roopa H. Nanjundappa, Urs Christen, Channakeshava S. Umeshappa
Summary: Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are two major autoimmune liver diseases. PBC primarily affects intrahepatic small bile duct epithelial cells in women, while PSC mainly affects medium and big bile duct epithelial cells in men. Cholangiocarcinoma (CCA) is a malignancy arising from cholangiocytes and is more prevalent in PSC patients than in PBC patients. Understanding the immune surveillance mechanisms that differentiate between PBC and PSC patients is crucial for developing effective therapies and early diagnosis of CCA.
HEPATOLOGY COMMUNICATIONS
(2023)
Article
Gastroenterology & Hepatology
Roopa H. Nanjundappa, Urs Christen, Channakeshava S. Umeshappa
Summary: Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are two significant autoimmune liver diseases. PBC primarily affects small bile duct epithelial cells in women, while PSC predominantly affects medium and large intrahepatic and extrahepatic bile duct epithelial cells in men. Cholangiocarcinoma (CCA) is a malignancy arising from cholangiocytes and its incidence is increasing worldwide. Although PBC patients rarely develop CCA compared to PSC patients, understanding the differences in immune surveillance mechanisms is crucial for effective diagnosis and treatment.
HEPATOLOGY COMMUNICATIONS
(2023)
Article
Gastroenterology & Hepatology
Daniel Iluz-Freundlich, Julia Uhanova, Micah Grubert Van Iderstine, Gerald Y. Minuk
Summary: By comparing the disease activity and severity of NAFLD/PBC and NAFLD alone patients, the findings suggest that PBC does not adversely affect the severity or course of NAFLD, and in some indicators, NAFLD/PBC patients showed better outcomes.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Na Young Lee, Min Jea Shin, Gi Soo Youn, Sang Jun Yoon, Ye Rin Choi, Hyeong Seop Kim, Haripriya Gupta, Sang Hak Han, Byoung Kook Kim, Do Yup Lee, Tae Sik Park, Hotaik Sung, Byung Yong Kim, Ki Tae Suk
Summary: The study found that NAFLD patients have abnormal composition of gut microbiota, and intake of Lactobacillus (such as L. acidophilus) can lower cholesterol levels and improve the progression of NAFLD.
CLINICAL AND MOLECULAR HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Surain B. Roberts, Gideon M. Hirschfield, Lawrence J. Worobetz, Catherine Vincent, Jennifer A. Flemming, Angela Cheung, Karim Qumosani, Mark Swain, Dusanka Grbic, Hin Hin Ko, Kevork Peltekian, Nazia Selzner, Lusine Abrahamyan, Bishoi Aziz, Ellina Lytvyak, Kattleya Tirona, Aliya F. Gulamhusein, Harry L. A. Janssen, Aldo J. Montano-Loza, Andrew L. Mason, Bettina E. Hansen
Summary: In a diverse Canadian cohort of PBC patients, Indigenous Canadians have poorer liver transplant-free and event-free survival compared to White patients. They are more likely to have a clinical event before diagnosis and present with higher liver function test indicators, which persist during follow-up.